Cargando…
Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL
The ALOX5 gene encodes 5-lipoxygenase (5-LO), a key enzyme of inflammatory reactions, which is transcriptionally activated by trichostatin A (TSA). Physiologically, 5-LO expression is induced by calcitriol and/or transforming growth factor-β. Regulation of 5-LO mRNA involves promoter activation and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259963/ https://www.ncbi.nlm.nih.gov/pubmed/25402609 http://dx.doi.org/10.1038/oncsis.2014.39 |
_version_ | 1782348097172537344 |
---|---|
author | Ahmad, K Katryniok, C Scholz, B Merkens, J Löscher, D Marschalek, R Steinhilber, D |
author_facet | Ahmad, K Katryniok, C Scholz, B Merkens, J Löscher, D Marschalek, R Steinhilber, D |
author_sort | Ahmad, K |
collection | PubMed |
description | The ALOX5 gene encodes 5-lipoxygenase (5-LO), a key enzyme of inflammatory reactions, which is transcriptionally activated by trichostatin A (TSA). Physiologically, 5-LO expression is induced by calcitriol and/or transforming growth factor-β. Regulation of 5-LO mRNA involves promoter activation and elongation control within the 3′-portion of the ALOX5 gene. Here we focused on the ALOX5 promoter region. Transcriptional initiation was associated with an increase in histone H3 lysine 4 trimethylation in a TSA-inducible manner. Therefore, we investigated the effects of the MLL (mixed lineage leukemia) protein and its derivatives, MLL-AF4 and AF4-MLL, respectively. MLL-AF4 was able to enhance ALOX5 promoter activity by 47-fold, which was further stimulated when either vitamin D receptor and retinoid X receptor or SMAD3/SMAD4 were co-transfected. In addition, we investigated several histone deacetylase inhibitors (HDACi) in combination with gene knockdown experiments (HDAC1-3, MLL). We were able to demonstrate that a combined inhibition of HDAC1-3 induces ALOX5 promoter activity in an MLL-dependent manner. Surprisingly, a constitutive activation of ALOX5 by MLL-AF4 was inhibited by class I HDAC inhibitors, by relieving inhibitory functions deriving from MLL.Conversely, a knockdown of MLL increased the effects mediated by MLL-AF4. Thus, HDACi treatment seems to switch ‘inactive MLL' into ‘active MLL' and overwrites the dominant functions deriving from MLL-AF4. |
format | Online Article Text |
id | pubmed-4259963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42599632014-12-12 Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL Ahmad, K Katryniok, C Scholz, B Merkens, J Löscher, D Marschalek, R Steinhilber, D Oncogenesis Original Article The ALOX5 gene encodes 5-lipoxygenase (5-LO), a key enzyme of inflammatory reactions, which is transcriptionally activated by trichostatin A (TSA). Physiologically, 5-LO expression is induced by calcitriol and/or transforming growth factor-β. Regulation of 5-LO mRNA involves promoter activation and elongation control within the 3′-portion of the ALOX5 gene. Here we focused on the ALOX5 promoter region. Transcriptional initiation was associated with an increase in histone H3 lysine 4 trimethylation in a TSA-inducible manner. Therefore, we investigated the effects of the MLL (mixed lineage leukemia) protein and its derivatives, MLL-AF4 and AF4-MLL, respectively. MLL-AF4 was able to enhance ALOX5 promoter activity by 47-fold, which was further stimulated when either vitamin D receptor and retinoid X receptor or SMAD3/SMAD4 were co-transfected. In addition, we investigated several histone deacetylase inhibitors (HDACi) in combination with gene knockdown experiments (HDAC1-3, MLL). We were able to demonstrate that a combined inhibition of HDAC1-3 induces ALOX5 promoter activity in an MLL-dependent manner. Surprisingly, a constitutive activation of ALOX5 by MLL-AF4 was inhibited by class I HDAC inhibitors, by relieving inhibitory functions deriving from MLL.Conversely, a knockdown of MLL increased the effects mediated by MLL-AF4. Thus, HDACi treatment seems to switch ‘inactive MLL' into ‘active MLL' and overwrites the dominant functions deriving from MLL-AF4. Nature Publishing Group 2014-11 2014-11-17 /pmc/articles/PMC4259963/ /pubmed/25402609 http://dx.doi.org/10.1038/oncsis.2014.39 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/4.0/ Oncogenesis is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Original Article Ahmad, K Katryniok, C Scholz, B Merkens, J Löscher, D Marschalek, R Steinhilber, D Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL |
title | Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL |
title_full | Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL |
title_fullStr | Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL |
title_full_unstemmed | Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL |
title_short | Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL |
title_sort | inhibition of class i hdacs abrogates the dominant effect of mll-af4 by activation of wild-type mll |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259963/ https://www.ncbi.nlm.nih.gov/pubmed/25402609 http://dx.doi.org/10.1038/oncsis.2014.39 |
work_keys_str_mv | AT ahmadk inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll AT katryniokc inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll AT scholzb inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll AT merkensj inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll AT loscherd inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll AT marschalekr inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll AT steinhilberd inhibitionofclassihdacsabrogatesthedominanteffectofmllaf4byactivationofwildtypemll |